Although therapies based on GLP‐1 physiology have been highly successful in the treatment of type 2 diabetes, the alteration of intestinal salt and water balance has recently been recognized as a promising target for novel drugs against hypertension, heart failure, end‐stage renal disease and chronic kidney disease (Spencer et al. The gene discussed is GLP1R; the disease is heart failure.